SARS-CoV-2 induced lymphopenia leading to novel PML infection

Murray, Ann; Major, Imani; Nestor, Nicholas; Sblendorio, Danielle

doi:10.1016/j.nerep.2022.100115

Cited by 4 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, JCPyV seroconversion rates have been reported to be stable during the COVID-19 pandemic, [162], but some data indicate that HIV/AIDS prevalence may increase in the post-COVID-19 period [163][164][165][166][167]. Rare reports describe novel PML manifestations due to SARS-CoV-2 [168]. Even if the incidence of PML has increased dramatically after the onset of the AIDS pandemic, and taking into account the previous facts on the COVID-19 pandemic, PML may be more common either in the elderly population or with some new forms as well as clinical and imaging manifestations and laboratory analyses.…”

Section: The Expert Opinion-demystifying Jcpyv and Pmlmentioning

confidence: 99%

John Cunningham Virus and Progressive Multifocal Leukoencephalopathy: A Falsely Played Diagnosis

Mouliou

2024

Diseases

View full text Add to dashboard Cite

Progressive Multifocal Leukoencephalopathy (PML) is a possibly fatal demyelinating disease and John Cunningham Polyomavirus (JCPyV) is believed to cause this condition. The so-called JCPyV was initially reported in lymphoma and Human Immunodeficiency Virus (HIV) cases, whereas nowadays, its incidence is increasing in Multiple Sclerosis (MS) cases treated with natalizumab (Tysabri). However, there are conflicting literature data on its pathology and diagnosis, whereas some misdiagnosed reports exist, giving rise to further questions towards the topic. In reality, the so-called PML and the supposed JCPyV are not what they seem to be. In addition, novel and more frequent PML-like conditions may be reported, especially after the Coronavirus Disease 2019 (COVID-19) pandemic.

show abstract